Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study

Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or –resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m2) or high (2-4 doses of 375 mg/m2) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9–17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 ± 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.Key words: Frequently relapsing nephrotic syndrome, immunosuppressive agents, steroid-dependent nephrotic syndrome, steroidresistant nephrotic syndrome, remission

PDF

___

1. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney International 1978; 13(2): 159-165. doi: 10.1038/ki.1978.23
2. Hodson E, Knight JJF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database of Systematic Reviews 2002; doi: 10.1002/14651858. CD001533
3. Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. Journal of the American Society of Nephrology 2013; 24b(1): 149-159. doi: 10.1681/ASN.2012070646
4. Kemper MJ, Lehnhardt A, Zawischa A, Oh J. Is rituximab effective in childhood nephrotic syndrome? Yes and no. Pediatric Nephrology 2014; 29: 1305-1311. doi: 10.1007/ s00467-013-2529-1
5. Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrology Dialysis Transplantation 2015; 30: 96–106. doi.org/10.1093/ndt/gfu267
6. Iijima K, Sako M, Nozu K, Mori R, Tuchida N et al. Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet 2014; 384: 1273–1281. doi: 10.1016/S0140-6736(14)60541-9
7. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L et al. Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Journal of the American Society of Nephrology 2014; 25(4): 850-863. doi: 10.1681/ ASN.2013030251
8. Topaloğlu R, Gülhan B, Çelegen K, İnözü M, Hayran M et al. Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth. Frontiers in Pediatrics 2019; doi: 10.3389/fped.2019.00313
9. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L et al. Rituximab in children with resistant idiopathic nephrotic syndrome. Journal of the American Society of Nephrology 2012; 23(6): 1117-1124. doi: 10.1681/ASN.2011080775
10. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. The New England Journal of Medicine 2007; 356(26): 2751-2752. doi: 10.1056/ NEJMc063706
11. Fujinaga S, Sakuraya K. Repeated administrations of rituximab along with steroids and immunosuppressive agents in refractory steroid-resistant nephrotic syndrome. Indian Pediatrics 2017; 54: 49–50. doi.org/10.1007/s13312-017-0996-3
12. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery. Nephrology Dialysis Transplantation 2012; 27(3): 1083-1089. doi: 10.1093/ndt/gfr405
13. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatric Nephrology 2013; 28(2): 257-264. doi: 10.1007/s00467-012-2319-1
14. Bonanni A, Calatroni M, D’Alessandro M, Signa S, Bertelli E et al. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. British Journal of Clinical Pharmacology 2018; 84(6):1238-1249. doi: 10.1111/bcp.13548
15. Trivin C, Tran A, Moulin B, Choukroun G, Gatault P et al. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clinical Kidney Journal 2017; 10(4): 461-469. doi: 10.1093/ckj/sfw101
16. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. Journal of the American Society of Nephrology 1997; 8(5):769-776
17. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A et al. International Pediatric Nephrology Association IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatric Nephrology 2020; 35(8): 1529-1561. doi: 10.1007/ s00467-020-04519-1
18. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A et al. Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. Journal of Clinical Research in Pediatric Endocrinology 2015; 7(4): 280-293. doi: 10.4274/jcrpe.2183
19. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clinical Journal of the American Society of Nephrology 2009; 4(11): 1832-1843. doi: 10.2215/ CJN.01640309
20. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatric Nephrology 2009; 24 (7): 1321-1328. doi: 10.1007/s00467-009-1191-0
21. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrology Dialysis Transplantation 2012; 27(5): 1910-1915. doi: 10.1093/ndt/ gfr548
22. Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A et al. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatric Nephrology 2019; 34(1):87-96. doi:10.1007/s00467-018-4063-7
23. Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ et al. Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney International 2020; 97(2): 393-401. doi: 10.1016/j.kint.2019.09.033
24. Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E et al. Rituximab in refractory nephrotic syndrome. Pediatric Nephrology 2010; 25(3): 461-468. doi: 10.1007/s00467-009- 1376-6
25. Kamei K, Ishikura K, Sako M, Ito S, Nozu K et al. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children. Pediatric Nephrology 2020; 35(1): 17-24. doi: 10.1007/s00467-018-4166-1
26. Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y et al. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. Pediatric Nephrology 2019; 34(2): 353- 357. doi: 10.1007/s00467-018-4145-6
27. Zachwieja J, Silska-Dittmar M, Żurowska A, DrożyńskaDuklas M, Hyla-Klekot L et al. Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome. Clinical and Experimental Pharmacology and Physiology 2018; doi: 10.1111/1440-1681.13046
28. Girişgen İ, Yüksel S, Pekal Y. Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turkish Archives of Pediatrics 2020; 9;55(1): 60-66. doi: 10.14744/TurkPediatriArs.2019.76148
29. Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatric Nephrology 2019; 34(5): 855-863. doi: 10.1007/s00467-018-4172-3
30. Hogan J, Dossier C, Kwon T, Macher MA, Maisin A et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatric Nephrology 2019; 34(2): 253-259. doi: 10.1007/s00467-018-4052-x
31. Ito S, Kamei K, Ogura M, Sato M, Fujimaru T et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatric Nephrology 2011; 26: 1823–1828. doi: 10.1007/ s00467-011-1886-x
32. Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. European Journal of Pediatrics 2013; 172(4): 513-518. doi: 10.1007/s00431-012-1913-3
33. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatric Nephrology 2008; 23(8): 1269-1279. doi: 10.1007/s00467-008-0814-1
34. Spatafora M, Bellini T, Giordano C, Ghiggeri GM. A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome. BMJ Case Reports 2015; doi: 10.1136/ bcr-2015-212694
35. Morita K, Shibano T, Maekawa K, Hattori M, Hida N et al. Crohn’s disease following rituximab treatment in a patient with refractory nephrotic syndrome. Clinical and Experimental Nephrology Case Reports 2019; 8(1): 55-60. doi: 10.1007/ s13730-018-0364-8
36. Galassi G, Testa F, Bianchi F, Cappelli G, Chiari A. Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome. Clinical and Experimental Nephrology Case Reports 2017; 6(2): 215-216. doi: 10.1007/s13730-017-0264-3
37. Sellier-Leclerc AL, Belli E, Guérin V, Dorfmüller P, Deschênes G. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatric Nephrology 2013; 28(9): 1875-1879. doi: 10.1007/s00467-013-2485-9
38. Sato M, Ito S, Ogura M, Kamei K, Miyairi I et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatric Nephrology 2013; 28(1): 145-149. doi: 10.1007/ s00467-012-2286-6
39. Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T. Lateonset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clinical Nephrology 2016; 85(6):340-345. doi: 10.5414/ CN108835